FDA approves J&J prostate cancer treatment

(Reuters) – The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.

Source: Reuters Medical News